As 2024 draws to a close, Ophthalmology Times reflects on a year marked by significant advancements in eye care, especially in the realms of artificial intelligence (AI) and sustainability. The publication highlights a range of emerging topics, encompassing the growth of AI technology in healthcare, which has prompted experts to call for careful accuracy verification.
One of the pivotal discussions covered in the magazine revolves around the use of AI in ophthalmology, including the critical need for healthcare professionals to validate AI-generated results. The magazine featured twelve cover stories throughout the year, delving into diverse subjects. Notably, advancements in virtual reality (VR) technologies have been spotlighted for their role in enhancing collaboration during medical conferences.
In an article discussing best practices in surgical efficiency, Eric D. Rosenberg, a cornea complex anterior segment surgeon at SightMD in Babylon, New York, emphasised the continual push for improved performance in cataract surgery. He remarked, “I have spent the past few years focusing on performing better, faster, and more accurate surgery. Modern cataract surgery is extremely safe and efficient, and technological advances have led to more predictable surgery in fewer steps. It therefore can be challenging to find further efficiencies. Focusing on small changes while maintaining a routine is key."
The magazine also showcased efforts aimed at sustainability within the field of ophthalmology. EyeSustain, an organisation dedicated to promoting environmentally friendly practices, was featured for its global initiative to educate and support sustainable methods in eye care.
Further explorations into future treatment possibilities included discussions on recently approved biosimilars for retinal diseases. A particular highlight was the introduction of a new canalicular gel device called Lacrifill by Nordic Pharma, expected to address dry eye disease (DED).
The topic of dry eye emerged as a significant focus in 2024, drawing attention to the increasing challenges patients face in understanding the condition and its treatment options. Notably, Aldeyra Therapeutics received approval for reproxalap from the FDA, marking a notable advancement after overcoming a complete response letter (CRL) issued in late 2023. A survey conducted by Bausch + Lomb further illuminated the issue, revealing gaps in patient knowledge regarding the severity of DED.
Research also underscored the influence of environmental factors on dry eye patients. Studies indicated that exposure to certain air pollutants and lower temperatures could exacerbate symptoms, linking clinical visits to levels of air pollution.
In terms of clinical developments, numerous trials continued to progress in the background of 2024, with companies like Sun Pharma announcing positive results for its cyclosporine ophthalmic solution, and Oculis Holding AG revealing successful outcomes from its Phase 2b RELIEF trial.
The FDA remained active in approving new treatment options this past year, most notably in the realm of ophthalmology. In October, Bausch + Lomb announced the FDA's approval of the enVista Envy intraocular lenses (IOLs) that provide a continuous range of vision. Earlier in the summer, Genentech’s faricimab-svoa (Vabysmo) received approval for treating conditions such as wet age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion. Additionally, several biosimilars were launched, including Formycon’s version of Eylea and others from Biocon Biologics and Samsung Bioepis.
As technological innovations in AI and sustainability continue to shape the future of ophthalmology, the Ophthalmology Times and the Eye Care Network commit to delivering timely insights, expert analyses, and updates within the industry. This year has seen considerable progress, and the community looks forward to ongoing advancements as we transition into 2025.
Source: Noah Wire Services